TG TherapeuticsTGTX

Key highlights

• Core product revenue surging: Briumvi U.S. sales grew 64% to $227.7 million compared to the same period last year, showing that the company's main multiple sclerosis drug is gaining significant market share. The drug is now on a path to reach a $1 billion annual sales rate in the U.S. by the end of the year.
• Revenue guidance raised: Management raised its full year 2026 total revenue target to $950 million, up from the previous goal of $885 million to $900 million. This higher outlook reflects stronger than expected demand for Briumvi and gives investors more confidence in the company's growth trajectory.
• Operating expenses climbing: Research and development costs jumped to $95.3 million from $31.8 million a year ago, primarily because the company spent $54.6 million on manufacturing setup for a new under the skin version of its drug. While these costs lowered quarterly profit, they are necessary to bring a more convenient product to market.
• Briumvi treatment simplified: A clinical trial called ENHANCE met its goal by proving a single 600 mg dose is just as effective as the current two dose starting regimen. This should make the drug more attractive to patients and doctors by cutting out an extra clinic visit on the fifteenth day of treatment.
• Clinical pipeline expanding: The company began a new phase 2 study for Briumvi to treat schizophrenia and is moving forward with a study for myasthenia gravis, a chronic muscle weakness disorder. These trials aim to prove the drug works for conditions beyond multiple sclerosis, which could eventually multiply the number of patients the company can serve.

Our take: This was a strong quarter defined by the rapid takeoff of Briumvi and a confident lift to full year sales targets. While higher manufacturing and clinical costs weighed on the bottom line this quarter, they represent an investment in a more convenient version of the drug. The clear commercial success reinforces the case for long term growth.